Restarting Jardiance (Empagliflozin) After Acute Illness: A Clinical Guide

Why Empagliflozin Carries Unique Sick-Day Risk

Empagliflozin is not a passive glucose-lowering pill. It actively forces the kidney to excrete 60 to 90 grams of glucose per day through urine, regardless of ambient insulin levels. That mechanism, which drives the drug's cardiovascular and renal benefits, becomes a liability during acute illness.

The Euglycemic DKA Problem

During physiological stress, counter-regulatory hormones suppress insulin secretion and accelerate lipolysis. When empagliflozin simultaneously drains glucose into the urine, the plasma glucose may stay deceptively normal even as ketone production accelerates. This is euglycemic diabetic ketoacidosis (euDKA), and it is the single most dangerous complication tied to sick-day SGLT2 inhibitor use.

The FDA issued a Drug Safety Communication in 2015 specifically flagging euDKA with the entire SGLT2 inhibitor class, including empagliflozin. The agency noted that in reported cases, blood glucose was often <250 mg/dL, a threshold that would normally reassure both patient and clinician that DKA was not occurring [1]. The clinical lesson: a normal fingerstick does not rule out DKA in a patient who is still taking empagliflozin.

Volume Depletion Compounds the Risk

Osmotic diuresis from glucosuria produces an obligate fluid loss of roughly 375 mL per day at steady state in healthy adults. Add vomiting, diarrhea, fever, or reduced oral intake, and that volume deficit becomes clinically significant within hours. Volume contraction raises hematocrit, activates the renin-angiotensin-aldosterone system, and can precipitate acute kidney injury, especially in older adults or those concurrently taking ACE inhibitors, ARBs, or diuretics [2].

Infection Risk Is Real but Manageable

Glucosuria creates a substrate-rich urinary environment. Genital mycotic infections are the most common adverse effect of empagliflozin overall, reported in 3.4% of women and 1.0% of men in the EMPA-REG OUTCOME trial (N = 7,020) [3]. Urinary tract infections are less clearly elevated with empagliflozin than with older-generation SGLT2 inhibitors, but any active UTI or genitourinary infection should prompt a hold until the infection resolves and antibiotics are complete.

The EMPA-REG OUTCOME Trial: Why the Benefits Are Worth Protecting

Before addressing when to hold the drug, it is worth anchoring the clinical stakes. EMPA-REG OUTCOME enrolled 7,020 adults with type 2 diabetes and established cardiovascular disease, randomizing them to empagliflozin 10 mg, 25 mg, or placebo on top of standard care [3].

Cardiovascular Outcomes

At a median follow-up of 3.1 years, empagliflozin reduced the three-point MACE composite (CV death, non-fatal MI, non-fatal stroke) by 14% (HR 0.86, 95% CI 0.74-0.99, P = 0.04 for superiority) [3]. The mortality signal was even sharper: CV death fell by 38% (HR 0.62, 95% CI 0.49-0.77, P <0.001) [3].

That 38% reduction in CV death was achieved largely within the first 3 months of the trial, suggesting a hemodynamic mechanism, most likely the natriuretic and diuretic effects of SGLT2 inhibition, rather than atherosclerosis regression [3]. A patient who holds Jardiance inappropriately for two weeks following a mild gastroenteritis may be surrendering exactly that early hemodynamic benefit.

Renal Outcomes

The subsequent EMPA-KIDNEY trial (N = 6,609) confirmed that empagliflozin 10 mg reduced the composite of kidney disease progression or CV death by 28% (HR 0.72, 95% CI 0.64-0.82, P <0.001) in patients with eGFR as low as 20 mL/min/1.73 m² [4]. The FDA approved the CKD indication in 2023 on the basis of this data, and it explicitly lowered the minimum eGFR threshold to 20 for the heart failure and CKD indications.

Conditions That Require an Immediate Hold

The 2024 American Diabetes Association Standards of Care state that SGLT2 inhibitors should be held "during acute illness associated with dehydration, reduced caloric intake, or hemodynamic instability" [5]. The following clinical scenarios each meet that bar independently.

Gastrointestinal Illness

Any vomiting or diarrhea lasting more than 4 hours is sufficient reason to hold empagliflozin the same day. The patient does not need to be admitted to a hospital. Even outpatient gastroenteritis reduces oral intake, accelerates dehydration, and activates the counter-regulatory response that underpins euDKA [6].

Practical instruction: Patients should be counseled to hold the pill on any morning they cannot keep fluids down, and to call the prescribing clinician if vomiting persists beyond 24 hours or if they develop abdominal pain.

Fever and Systemic Infection

Fever above 38.5°C reliably elevates cortisol and glucagon. These hormones suppress insulin, accelerate hepatic ketogenesis, and increase insulin requirements. A febrile patient taking empagliflozin is at elevated euDKA risk even if they appear to be eating and drinking reasonably well.

Hold empagliflozin at the onset of fever above 38.5°C. Restart only after the patient is afebrile for 24 hours and has returned to normal oral intake.

Surgery and Procedural Fasting

The Society for Endocrinology and Diabetes UK guidelines, endorsed by multiple professional bodies, recommend holding SGLT2 inhibitors a minimum of 3 days before elective surgery [7]. The American Diabetes Association's 2024 perioperative guidance aligns with this, recommending omission before any procedure requiring fasting [5].

The rationale is two-fold. First, intraoperative stress hormones mirror the physiological environment that triggers euDKA. Second, the combination of preoperative fasting and intraoperative hypotension can acutely reduce GFR, concentrating the drug and prolonging its tubular effects past expected pharmacokinetic clearance.

IV Contrast Administration

Radiocontrast agents carry a small but real risk of contrast-induced nephropathy. Because empagliflozin's glycemic and renoprotective efficacy depends on adequate tubular function, and because a sudden drop in GFR post-contrast can trigger drug accumulation and volume depletion, standard radiology practice is to hold the drug on the day of contrast administration and for 48 hours afterward, pending a creatinine check [5].

Step-by-Step Restart Protocol

Restarting empagliflozin after an acute illness is not simply a matter of telling the patient to take the pill again. A structured clinical assessment reduces the risk of restarting into an unsafe physiological state.

Step 1: Confirm Full Oral Intake

The patient must be tolerating a full diet and adequate fluids for at least 24 consecutive hours before restart is considered. "Adequate" means no vomiting, no persistent nausea limiting intake, and urine output that is visually normal in color and frequency. Concentrated, dark urine signals ongoing dehydration and is an absolute hold on restart.

Step 2: Check Renal Function

A point-of-care or laboratory serum creatinine should be obtained. Calculate the current eGFR using the CKD-EPI 2021 equation.

• eGFR ≥30 mL/min/1.73 m²: restart is appropriate for all approved indications
• eGFR 20-29 mL/min/1.73 m²: restart is appropriate for heart failure and CKD indications only; glycemic dosing should not be the primary justification
• eGFR <20 mL/min/1.73 m²: hold empagliflozin and reassess in 5 to 7 days

Note that eGFR may be transiently reduced during acute illness due to volume contraction, not true structural kidney injury. A creatinine drawn on day 1 of recovery may overestimate the degree of renal impairment. If the value is borderline, repeat the test in 48 hours before making a final restart decision.

Step 3: Rule Out Ketosis

Before restarting, either a urine ketone dipstick or a point-of-care blood beta-hydroxybutyrate (BHB) should be checked.

• Urine ketones negative or trace: restart is appropriate
• Urine ketones moderate to large: obtain serum BHB; if BHB >1.0 mmol/L, do not restart and refer for urgent evaluation
• Any patient with abdominal pain, nausea, or tachycardia despite appearing clinically recovered should have serum BHB checked regardless of urine ketone result

Step 4: Assess Hemodynamics

Blood pressure should be at or above 90/60 mmHg without vasopressors or aggressive IV fluid resuscitation. A patient who is recently stabilized after septic shock is not an appropriate restart candidate on day 2 of a step-down unit admission, even if they are eating. Allow at minimum 48 hours of hemodynamic stability off vasopressors before restarting.

Step 5: Review Concurrent Medications

Empagliflozin's diuretic effect is additive with loop diuretics, thiazides, and mineralocorticoid receptor antagonists. During acute illness, diuretic regimens are often adjusted. Confirm the current diuretic dose is appropriate before restarting empagliflozin to avoid overcorrection. Patients on lithium should have a lithium level checked, as volume contraction can raise lithium to toxic concentrations.

Step 6: Restart at the Established Dose

There is no clinical evidence supporting a dose-reduction strategy upon restart. Once all five prior steps are confirmed, resume empagliflozin at the patient's pre-illness dose (10 mg or 25 mg once daily with or without food). The FDA-approved labeling does not recommend re-titration after a temporary hold [8].

Special Populations Requiring Modified Restart Criteria

Heart Failure Patients

Empagliflozin was approved for heart failure with reduced and preserved ejection fraction based on the EMPEROR-Reduced (N = 3,730) and EMPEROR-Preserved (N = 5,988) trials [9, 10]. In EMPEROR-Reduced, empagliflozin 10 mg reduced the composite of CV death or hospitalization for heart failure by 25% (HR 0.75, 95% CI 0.65-0.86, P <0.001) [9].

Heart failure patients represent a population where a premature hold may be especially harmful, given that the drug's hemodynamic and natriuretic benefits are part of their active decompensation management. Conversely, they are also more vulnerable to volume overload if dehydration during illness leads to aggressive IV fluid resuscitation that must later be diuresed off. The restart decision in this group should be made in communication with the patient's cardiologist if they were recently hospitalized for acute decompensated heart failure.

Older Adults

Adults over 75 years have reduced renal reserve, less strong thirst mechanisms, and a higher baseline risk of orthostatic hypotension. A fall in eGFR during acute illness that would be transient in a 50-year-old may persist for 5 to 10 days in a 78-year-old. Apply a more conservative restart timeline, and prioritize the creatinine recheck before resuming.

Type 1 Diabetes (Off-Label Use)

Empagliflozin is not FDA-approved for type 1 diabetes. Clinicians prescribing it off-label should follow even stricter sick-day rules. Patients with type 1 have near-absent endogenous insulin, making them substantially more susceptible to ketoacidosis during counter-regulatory hormone surges. A 2019 review in Diabetes Care concluded that the absolute risk of DKA with SGLT2 inhibitors in type 1 diabetes is 4 to 6 times higher than in type 2 [6]. Any acute illness in a type 1 patient taking empagliflozin off-label warrants same-day discontinuation and serum BHB measurement.

Patient Education: What to Tell Patients Before They Leave the Clinic

Patient understanding of sick-day rules is directly associated with DKA rates. A 2021 audit in Australia found that 61% of SGLT2 inhibitor-associated DKA cases occurred in patients who had not received structured sick-day education [11].

Three things every patient must know:

1. Hold the pill on any morning you cannot eat or drink normally. Do not wait to see if you feel better by noon.
2. A normal blood sugar does not mean you are safe. Ketoacidosis can develop with a glucose under 200 mg/dL.
3. Symptoms to watch for: nausea, abdominal pain, rapid breathing, or confusion. These require an emergency room visit, not a phone call.

Written sick-day action plans, similar to the format used in asthma and adrenal insufficiency management, improve adherence to hold-and-restart rules. The ADA recommends that clinicians provide written sick-day guidance at the time of SGLT2 inhibitor initiation [5].

Monitoring After Restart

A restart is not the end of the clinical encounter. The following labs should be checked 5 to 7 days after resuming empagliflozin following any illness requiring a hold of more than 3 days:

• Serum creatinine and eGFR: confirm return to baseline
• Serum electrolytes: hypokalemia and hyponatremia may persist post-illness
• Blood pressure: reassess for orthostatic changes, particularly if the patient lost significant fluid weight during illness

Blood glucose trends for the first 48 hours after restart are also worth reviewing, as the glycosuria-driven glucose lowering resumes promptly upon re-dosing. Patients using insulin concurrently may need a temporary basal reduction of 10 to 20% to avoid hypoglycemia during the re-equilibration period.

A Note on Drug Interactions During Illness

Acute illness frequently introduces new medications. Two interactions are worth flagging specifically in the restart context.

Trimethoprim (used in UTI treatment) inhibits tubular creatinine secretion and can artificially raise serum creatinine by 0.1 to 0.3 mg/dL without true GFR change [12]. A creatinine drawn while a patient is completing a trimethoprim course may appear to drop below the restart eGFR threshold when true GFR is actually adequate. Time the restart creatinine to be drawn 48 hours after trimethoprim is complete.

NSAIDs, frequently used for fever and pain during illness, are nephrotoxic through prostaglandin-mediated renal vasoconstriction. Concurrent NSAID and empagliflozin use during or immediately after illness compounds the risk of AKI. If the patient is still using NSAIDs at the time of planned restart, either substitute acetaminophen or delay restart until NSAIDs are stopped.

Clinician Summary: Hold-and-Restart Decision at a Glance

| Situation | Action | |---|---| | Vomiting or diarrhea, any duration | Hold immediately | | Fever > 38.5°C | Hold until afebrile 24 h | | Elective surgery | Hold 3 days before | | IV contrast | Hold day of and 48 h after | | eGFR <20 on recovery check | Hold; recheck in 5-7 days | | Positive urine ketones (moderate/large) | Hold; check serum BHB | | Full oral intake, eGFR ≥30, ketones negative | Restart at prior dose | | Heart failure/CKD, eGFR 20-29 | Restart with cardiology/nephrology input |

Patients on empagliflozin for established cardiovascular disease, heart failure, or CKD are taking a medication with outcome-level mortality data. The goal of sick-day rules is not to keep the drug withheld as long as possible. The goal is to resume it safely and promptly once the acute risk window has closed.